Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Summer;19(2):131-137.
doi: 10.31486/toj.18.0044.

Curative Therapies for Sickle Cell Disease

Kirshma Khemani  1   2 , Deeksha Katoch  1   2 , Lakshmanan Krishnamurti  1   2
Affiliations
Review

Curative Therapies for Sickle Cell Disease

Kirshma Khemani et al. Ochsner J. 2019 Summer.

Abstract

Background: Sickle cell disease (SCD) is an inherited hemoglobinopathy associated with severe morbidity, impaired quality of life, and premature mortality. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for patients with SCD and has a >90% event-free survival when a matched related donor is used. However, availability of human leukocyte antigen (HLA)-identical sibling donors for the SCD population is limited. The use of HLA-matched unrelated donors or related haploidentical donors has the potential to expand the donor pool. Methods: We reviewed the current literature on the indications for SCD transplantation, donor options, and the emerging use of gene therapy as a treatment option. Google Scholar and PubMed were searched using the terms SCD, bone marrow transplantation, donor sources, gene therapy, HSCT, and HLA matching. Additional articles were identified from the bibliographies of retrieved articles. All articles were reviewed for pertinent information related to SCD and transplantation. Results: HSCT has the potential to establish donor-derived normal erythropoiesis with stable long-term engraftment, amelioration of symptoms, and stabilization of organ damage. The majority of HSCT has been performed in children from HLA-identical sibling donors and has resulted in excellent rates of survival. The use of alternate donors such as HLA-matched unrelated donors and haploidentical donors has the potential to expand the applicability of HSCT for SCD. Early results in gene therapy for SCD are encouraging. Conclusion: Evaluation of the long-term benefits of curative therapies for SCD requires comparative clinical trials and studies of late effects.

Keywords: Anemia–sickle cell; bone marrow transplantation; genetic therapy; stem cell transplantation.

PubMed Disclaimer

References

    1. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. www.cdc.gov/ncbddd/sicklecell/data.html. Updated August 9, 2017. Accessed April 9, 2019.
    1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010. April;38(4 Suppl):S512-S521. doi: 10.1016/j.amepre.2009.12.022. - DOI - PubMed
    1. Piel FB, Patil AP, Howes RE, et al. . Global epidemiology of sickle hemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013. Jan 12;381(9861):142-151. doi: 10.1016/S0140-6736(12)61229-X. - DOI - PMC - PubMed
    1. Bhatia M, Sheth S. Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med. 2015. Jul 10;6:229- 238. doi: 10.2147/JBM.S60515. - DOI - PMC - PubMed
    1. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT 3rd. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984. Sep 20;311(12):780-783. - PubMed

LinkOut - more resources